Can-Fite Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis
October 17 2017 - 7:00AM
Business Wire
- Can-Fite has distribution agreements
in Korea for Piclidenoson and Namodenoson
- Piclidenoson slated to enter Phase
III study in treatment of psoriasis in 2018
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a
biotechnology company advancing a pipeline of proprietary small
molecule drugs that address cancer, liver and inflammatory
diseases, today announced the Korean Intellectual Property Office
has issued patent No. 10-1741281 titled, “Pharmaceutical
Composition Comprising A3 Adenosine Receptor Agonist
(IB-MECA/CF-101) For Treatment of Psoriasis” for the Company’s lead
drug candidate Piclidenoson (CF101) in its psoriasis
indication.
Can-Fite has two distribution agreements in Korea including one
with Kwang Dong Pharmaceutical for Piclidenoson in the treatment of
rheumatoid arthritis and another with Chong Kun Dang for
Namodenoson in the treatment of liver cancer.
“Korea is an important market for us, as evidenced by the two
distribution agreements we already have there. This patent may
increase the value of a potential distribution deal in Korea for
Piclidenoson in the treatment of psoriasis,” stated Can-Fite CEO
Dr. Pnina Fishman. “We believe Piclidenoson is a strong candidate
for the treatment of moderate to severe psoriasis due to its
excellent safety profile for long-term use and its favorable
comparison with Otezla®, the leading oral therapy currently on the
market.”
In an upcoming Phase III trial expected to commence in 2018,
Piclidenoson, administered orally, will be investigated compared to
placebo as its primary endpoint and as compared to apremilast
(Otezla®) as its secondary endpoint in approximately 400 patients
with moderate-to-severe plaque psoriasis. The psoriasis market is
forecast to be $8.9 billion in 2018 and Otezla® sales are estimated
to be $2.35 billion by 2020.
About Piclidenoson (CF101)
Piclidenoson is a novel, first-in-class, A3 adenosine receptor
agonist (A3AR) small molecule, orally bioavailable drug with a
favorable therapeutic index demonstrated in Phase II clinical
studies. Piclidenoson is currently under development for the
treatment of autoimmune inflammatory diseases including rheumatoid
arthritis (completed Phase II) and psoriasis (completed Phase
II/III).
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an
advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion dollar markets
in the treatment of cancer, inflammatory disease and sexual
dysfunction. The Company's lead drug candidate, Piclidenoson, is
scheduled to enter a Phase III trial for rheumatoid arthritis in
2017 and a Phase III trial for psoriasis in early 2018. The
rheumatoid arthritis Phase III protocol has recently been agreed
with the European Medicines Agency. Can-Fite's liver cancer drug
CF102 is in Phase II trials for patients with liver cancer and is
slated to enter Phase II for the treatment of non-alcoholic
steatohepatitis (NASH). CF102 has been granted Orphan Drug
Designation in the U.S. and Europe and Fast Track Designation as a
second line treatment for hepatocellular carcinoma by the U.S. Food
and Drug Administration. CF102 has also shown proof of concept to
potentially treat other cancers including colon, prostate, and
melanoma. CF602, the Company's third drug candidate, has shown
efficacy in the treatment of erectile dysfunction in preclinical
studies and the Company is investigating additional compounds,
targeting A3AR, for the treatment of sexual dysfunction. These
drugs have an excellent safety profile with experience in over
1,000 patients in clinical studies to date. For more information
please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite's expectations, beliefs or intentions regarding, among
other things, market risks and uncertainties, its product
development efforts, business, financial condition, results of
operations, strategies or prospects. In addition, from time to
time, Can-Fite or its representatives have made or may make
forward-looking statements, orally or in writing. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe," "expect," "intend," "plan," "may," "should" or
"anticipate" or their negatives or other variations of these words
or other comparable words or by the fact that these statements do
not relate strictly to historical or current matters. These
forward-looking statements may be included in, but are not limited
to, various filings made by Can-Fite with the U.S. Securities and
Exchange Commission, press releases or oral statements made by or
with the approval of one of Can-Fite's authorized executive
officers. Forward-looking statements relate to anticipated or
expected events, activities, trends or results as of the date they
are made. Because forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to
risks and uncertainties that could cause Can-Fite's actual results
to differ materially from any future results expressed or implied
by the forward-looking statements. Many factors could cause
Can-Fite's actual activities or results to differ materially from
the activities and results anticipated in such forward-looking
statements. Factors that could cause our actual results to differ
materially from those expressed or implied in such forward-looking
statements include, but are not limited to: the initiation, timing,
progress and results of our preclinical studies, clinical trials
and other product candidate development efforts; our ability to
advance our product candidates into clinical trials or to
successfully complete our preclinical studies or clinical trials;
our receipt of regulatory approvals for our product candidates, and
the timing of other regulatory filings and approvals; the clinical
development, commercialization and market acceptance of our product
candidates; our ability to establish and maintain corporate
collaborations; the implementation of our business model and
strategic plans for our business and product candidates; the scope
of protection we are able to establish and maintain for
intellectual property rights covering our product candidates and
our ability to operate our business without infringing the
intellectual property rights of others; estimates of our expenses,
future revenues, capital requirements and our needs for additional
financing; competitive companies, technologies and our industry;
statements as to the impact of the political and security situation
in Israel on our business; and risks and other risk factors
detailed in Can-Fite's filings with the SEC and in its periodic
filings with the TASE. In addition, Can-Fite operates in an
industry sector where securities values are highly volatile and may
be influenced by economic and other factors beyond its control.
Can-Fite does not undertake any obligation to publicly update these
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171017005297/en/
Can-Fite BioPharmaMotti Farbstein,
+972-3-9241114info@canfite.com
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2023 to Apr 2024